Richard Smykla

1.2k total citations
16 papers, 637 citations indexed

About

Richard Smykla is a scholar working on Genetics, Hematology and Oncology. According to data from OpenAlex, Richard Smykla has authored 16 papers receiving a total of 637 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Genetics, 9 papers in Hematology and 7 papers in Oncology. Recurrent topics in Richard Smykla's work include Chronic Lymphocytic Leukemia Research (10 papers), Chronic Myeloid Leukemia Treatments (9 papers) and Cancer Treatment and Pharmacology (4 papers). Richard Smykla is often cited by papers focused on Chronic Lymphocytic Leukemia Research (10 papers), Chronic Myeloid Leukemia Treatments (9 papers) and Cancer Treatment and Pharmacology (4 papers). Richard Smykla collaborates with scholars based in United States, Germany and Finland. Richard Smykla's co-authors include Francis Y. F. Lee, Robert A. Kramer, Gregory D. Vite, Craig R. Fairchild, Kelly McGlinchey, Francis Y. Lee, Feng Luo, R. M. Borzilleri, Mei-Li Wen and Amrita V. Kamath and has published in prestigious journals such as Blood, The Journal of Immunology and Cancer Research.

In The Last Decade

Richard Smykla

16 papers receiving 624 citations

Peers

Countries citing papers authored by Richard Smykla

Since Specialization

Citations

This map shows the geographic impact of Richard Smykla's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard Smykla with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard Smykla more than expected).

Fields of papers citing papers by Richard Smykla

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Richard Smykla. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard Smykla. The network helps show where Richard Smykla may publish in the future.

Co-authorship network of co-authors of Richard Smykla

This figure shows the co-authorship network connecting the top 25 collaborators of Richard Smykla. A scholar is included among the top collaborators of Richard Smykla based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Richard Smykla. Richard Smykla is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

#	Work	Indexed citations
1	Dasatinib Changes Immune Cell Profiles Concomitant with Reduced Tumor Growth in Several Murine Solid Tumor Models 2017 ·Cancer Immunology Research ·Can Hekim, Mette Ilander, Jun Yan, (unknown), Richard Smykla, Markus Vähä‐Koskela, Paula Savola, Siri Tähtinen, (unknown), Akseli Hemminki, Panu E. Kovanen, Kimmo Porkka, Francis Y. F. Lee, Satu Mustjoki	37
2	Rapid mobilization of cytotoxic lymphocytes induced by dasatinib therapy 2012 ·Leukemia ·Satu Mustjoki, Kaisa Auvinen, Anna Kreutzman, Philippe Rousselot, (unknown), Teresa Pinho e Melo, (unknown), Sampsa Hautaniemi, Stéphane Bouchet, Mathiéu Molimard, Richard Smykla, (unknown), Jukka Vakkila, S Jalkanen, Marko Salmi, Kimmo Porkka	70
3	Dasatinib Induces a Rapid, Dose-Controllable Mobilization of Cytotoxic Lymphocytes: A Novel Immunomodulatory Effect Associated with Prolonged Therapy Responses In Advanced Leukemia. 2010 ·Blood ·Satu Mustjoki, Philippe Rousselot, Sari E. Jalkanen, Anna Kreutzman, Teresa Pinho e Melo, (unknown), Sampsa Hautaniemi, Mathiéu Molimard, Richard Smykla, Francis Lee, Jukka Vakkila, Kimmo Porkka	7
4	Dasatinib potential for anti-inflammatory efficacy while avoiding suppression of T cell activation in preclinical models (33.8) 2009 ·The Journal of Immunology ·Gary L. Schieven, Rosemary Zhang, Sidney Pitt, Kim W. McIntyre, Kathleen M. Gillooly, Barry J. Brock, Richard Smykla, Robert Townsend, (unknown), Francis Lee	2
5	Molecular determinants of melanoma malignancy: selecting targets for improved efficacy of chemotherapy 2009 ·Molecular Cancer Therapeutics ·Jinming Yang, Snjezana Zaja‐Milatovic, Yee Mon Thu, Francis Lee, Richard Smykla, Ann Richmond	14
6	Preclinical efficacy spectrum and pharmacokinetics of ixabepilone 2008 ·Cancer Chemotherapy and Pharmacology ·Francis Y. F. Lee, Richard Smykla, Kathy Johnston, Krista Menard, Kelly McGlinchey, Russell W. Peterson, (unknown), Gregory D. Vite, Craig R. Fairchild, Robert A. Kramer	83
7	Preclinical discovery of ixabepilone, a highly active antineoplastic agent 2008 ·Cancer Chemotherapy and Pharmacology ·Francis Y. F. Lee, R. M. Borzilleri, Craig R. Fairchild, Amrita V. Kamath, Richard Smykla, Robert A. Kramer, Gregory D. Vite	88
8	Identification and validation of phospho-SRC, a novel and potential pharmacodynamic biomarker for dasatinib (SPRYCEL™), a multi-targeted kinase inhibitor 2008 ·Cancer Chemotherapy and Pharmacology ·Feng Luo, Yu Chen Barrett, Zheng Yang, Amy Camuso, Kelly McGlinchey, Mei-Li Wen, Richard Smykla, Krista Fager, Robert Wild, (unknown), Susan Galbraith, Anne Blackwood‐Chirchir, Francis Y. Lee	43
9	Preclinical Antitumor Activity of BMS-599626, a pan-HER Kinase Inhibitor That Inhibits HER1/HER2 Homodimer and Heterodimer Signaling 2006 ·Clinical Cancer Research ·Tai W. Wong, Francis Y. Lee, Chiang Yu, Feng Luo, Simone Oppenheimer, Hongjian Zhang, Richard Smykla, Harold Mastalerz, Brian E. Fink, John T. Hunt, Ashvinikumar V. Gavai, Gregory D. Vite	65
10	Dasatinib (BMS-354825) Pharmacokinetics and Pharmacodynamic Biomarkers in Animal Models Predict Optimal Clinical Exposure 2006 ·Clinical Cancer Research ·Feng Luo, Zheng Yang, Amy Camuso, Richard Smykla, Kelly McGlinchey, Krista Fager, Christine Flefleh, Stephen Castaneda, Ivan Inigo, David Kan, Mei-Li Wen, Robert A. Kramer, Anne Blackwood‐Chirchir, Francis Y. Lee	113
11	Dasatinib (BMS-354825) Overcomes Multiple Mechanisms of Imatinib Resistance in Chronic Myeloid Leukemia (CML). 2005 ·Blood ·Francis Y. Lee, Mei-Li Wen, Rajeev S. Bhide, Amy Camuso, (unknown), Krista Fager, Christine Flefleh, Ivan Inigo, David Kan, Roger Luo, Kelly McGlinchey, Richard Smykla, Robert A. Wild, R. M. Borzilleri, Louis J. Lombardo	14
12	Quiescent Chronic Myelogenous Leukemia (CML) Cells Are Resistant to BCR-ABL Inhibitors but Preferentially Sensitive to BMS-214662, a Farnesyltransferase Inhibitor (FTI) with Unique Quiescent-Cell Selective Cytotoxicity. 2005 ·Blood ·Francis Y. Lee, Mei-Li Wen, Amy Camuso, (unknown), Krista Fager, Christine Flefleh, Ivan Inigo, Roger Luo, David Kan, Veeraswamy Manne, Kelly McGlinchey, Richard Smykla, Roberto Weinmann, Robert A. Kramer	5
13	In vivo Evaluation of Ixabepilone (BMS247550), A Novel Epothilone B Derivative, against Pediatric Cancer Models 2005 ·Clinical Cancer Research ·Jennifer K. Peterson, Chandra L. Tucker, Edward Favours, Pamela J. Cheshire, (unknown), Catherine A. Billups, Richard Smykla, Francis Y. F. Lee, Peter J. Houghton	69
14	Apoptotic and Cytostatic Farnesyltransferase Inhibitors Have Distinct Pharmacology and Efficacy Profiles in Tumor Models 2004 ·Cancer Research ·Veeraswamy Manne, Francis Y. F. Lee, David K. Bol, Johnni Gullo-Brown, Craig R. Fairchild, Louis J. Lombardo, Richard Smykla, Gregory D. Vite, (unknown), Chiang Yu, Tai W. Wong, John T. Hunt	17
15	Pharmacokinetics- and Pharmacodynamics-Guided Optimization of the Dose and Treatment Schedule for the Dual SRC/ABL Inhibitor BMS-354825. 2004 ·Blood ·Feng Luo, Zheng Yang, Amy Camuso, Richard Smykla, (unknown), Christine Flefleh, Krista Fager, Ivan Inigo, David Kan, Kelly McGlinchey, Mei-Li Wen, Robert A. Wild, R. M. Borzilleri, Louis J. Lombardo, Robert A. Kramer, Francis Y. Lee	1
16	BMS-354825, a Dual SRC/ABL Kinase Inhibitor, Displays Potent Anti-Tumor Activity in a Model of Intracranial CML Growth. 2004 ·Blood ·Robert A. Wild, Stephen Castaneda, Christine Flefleh, Krista Fager, Ivan Inigo, David Kan, Richard Smykla, Amy Camuso, Kelly McGlinchey, Mei-Li Wen, Feng Luo, R. M. Borzilleri, Louis J. Lombardo, Robert A. Kramer, Francis Y. Lee	9

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact